Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian M Thompson

Showing results (271-280 of 484) with videos related to

Pageof 49
Sort By:
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|December 19, 2019
Electronic care coordination systems for people with advanced progressive illness: a mixed-methods evaluation in Scottish primary careAnne M Finucane, Deborah Davydaitis, Zoe Horseman, et al.
Urology|May 28, 2014
Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancerDonna P Ankerst, Josef Hoefler, Sebastian Bock, et al.
European Urology Focus|February 10, 2018
Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk CalculatorDonna P Ankerst, Martin Goros, Scott A Tomlins, et al.
The Journal of Urology|November 21, 2025
Joint Biochemical and Genetic Prostate Cancer Risk StratificationNicole Zeltser, Roni Haas, Christine Ibilibor, et al.
JAMA|November 16, 2006
Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trialIan M Thompson, Catherine M Tangen, Jorge Paradelo, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 8, 2012
Willingness to pay for prostate cancer treatment among patients and their family members at 1 year after diagnosisChunyu Li, Steven B Zeliadt, Ingrid J Hall, et al.
The Journal of Urology|July 4, 2006
Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group Study 9024Gregory P Swanson, James Faulkner, Stephen R Smalley, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 10, 2010
Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the Prostate Cancer Prevention TrialSiobhan Sutcliffe, Raphael P Viscidi, Cathee Till, et al.
Journal of the National Cancer Institute|August 28, 2016
Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention TrialJoseph M Unger, Cathee Till, Ian M Thompson, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 20, 2013
Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1 year after diagnosis: an economic perspectiveChunyu Li, Steven B Zeliadt, Ingrid J Hall, et al.
Pageof 49

Showing results (271-280 of 484) with videos related to

Sort By:
Pageof 49
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|December 19, 2019
Electronic care coordination systems for people with advanced progressive illness: a mixed-methods evaluation in Scottish primary careAnne M Finucane, Deborah Davydaitis, Zoe Horseman, et al.
Urology|May 28, 2014
Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancerDonna P Ankerst, Josef Hoefler, Sebastian Bock, et al.
European Urology Focus|February 10, 2018
Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk CalculatorDonna P Ankerst, Martin Goros, Scott A Tomlins, et al.
The Journal of Urology|November 21, 2025
Joint Biochemical and Genetic Prostate Cancer Risk StratificationNicole Zeltser, Roni Haas, Christine Ibilibor, et al.
JAMA|November 16, 2006
Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trialIan M Thompson, Catherine M Tangen, Jorge Paradelo, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 8, 2012
Willingness to pay for prostate cancer treatment among patients and their family members at 1 year after diagnosisChunyu Li, Steven B Zeliadt, Ingrid J Hall, et al.
The Journal of Urology|July 4, 2006
Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group Study 9024Gregory P Swanson, James Faulkner, Stephen R Smalley, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 10, 2010
Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the Prostate Cancer Prevention TrialSiobhan Sutcliffe, Raphael P Viscidi, Cathee Till, et al.
Journal of the National Cancer Institute|August 28, 2016
Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention TrialJoseph M Unger, Cathee Till, Ian M Thompson, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 20, 2013
Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1 year after diagnosis: an economic perspectiveChunyu Li, Steven B Zeliadt, Ingrid J Hall, et al.
Pageof 49